Health risk alert as weight-loss jab manufacturer warns over impurity in drug ‘knockoffs’
US drugmaker Eli Lilly has issued a public warning about potential health risks from compounded weight-loss drugs containing vitamin B12 and the active ingredient in its medication, Zepbound. The company stated on Thursday that a previously unidentified impurity, arising during preparation, could pose dangers to consumers.
This alert marks the latest move in Lilly's ongoing efforts against drug compounders, which it accuses of marketing illicit versions of Zepbound and its diabetes treatment, Mounjaro. Both drugs share the same key ingredient, tirzepatide. Lilly has initiated legal proceedings against various compounders, wellness centres, and other entities for selling products claiming to contain tirzepatide.
Conversely, compounders maintain their offerings are legitimate under a specific federal law. This provision permits compounding when patients require tailored medications due to medical concerns, such as the inclusion of vitamins or dosages not available in branded product..
